Free Trial

SIGA Technologies Target of Unusually High Options Trading (NASDAQ:SIGA)

SIGA Technologies logo with Medical background

SIGA Technologies, Inc. (NASDAQ:SIGA - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Traders acquired 1,200 call options on the company. This is an increase of 1,438% compared to the typical daily volume of 78 call options.

SIGA Technologies Stock Down 3.4 %

Shares of SIGA stock traded down $0.21 during trading hours on Friday, hitting $5.91. 590,324 shares of the company's stock traded hands, compared to its average volume of 372,314. The stock has a market cap of $421.97 million, a PE ratio of 4.93 and a beta of 0.94. SIGA Technologies has a 12 month low of $4.75 and a 12 month high of $12.83. The stock's 50 day simple moving average is $6.11 and its 200 day simple moving average is $7.07.

Institutional Investors Weigh In On SIGA Technologies

Institutional investors and hedge funds have recently made changes to their positions in the stock. Larson Financial Group LLC bought a new position in SIGA Technologies during the 3rd quarter worth approximately $30,000. Teacher Retirement System of Texas raised its stake in SIGA Technologies by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 12,829 shares of the company's stock worth $77,000 after buying an additional 2,126 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in SIGA Technologies in the fourth quarter valued at $78,000. EP Wealth Advisors LLC bought a new stake in SIGA Technologies during the third quarter valued at $82,000. Finally, Sherbrooke Park Advisers LLC acquired a new stake in SIGA Technologies during the 4th quarter worth about $83,000. Institutional investors and hedge funds own 55.40% of the company's stock.

SIGA Technologies Company Profile

(Get Free Report)

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Featured Stories

Should You Invest $1,000 in SIGA Technologies Right Now?

Before you consider SIGA Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SIGA Technologies wasn't on the list.

While SIGA Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines